Lobe Sciences Advances Conjugated Psilocin Development with Cynaptec Spin-Out

Lobe Sciences Ltd. continues to progress its Conjugated Psilocin™ development through its new subsidiary, Cynaptec Pharmaceuticals. This move follows an agreement from April 14, allowing Cynaptec to hold global rights to the compound. A recent $6 million investment will fund preclinical research and early clinical trials targeting chronic cluster headaches and addiction.

Cynaptec also has the option for an additional $20 million investment to support Phase 3 clinical development. Chronic cluster headaches, affecting over 60,000 in the U.S., currently lack FDA-approved treatments.

Launching Cynaptec, Lobe retains a 64% hold while advancing treatment options with Conjugated Psilocin™, designed for enhanced bioavailability without hallucinations. In parallel, Lobe introduces Altemia® Medical Food to manage long-chain fatty acid deficiencies in Sickle Cell Disease.